Modality
Small Molecule
MOA
PD-L1i
Target
FXIa
Pathway
Angiogenesis
GBM
Development Pipeline
Preclinical
~Sep 2019
→ ~Dec 2020
Phase 1
~Mar 2021
→ ~Jun 2022
Phase 2
~Sep 2022
→ ~Dec 2023
Phase 3
Mar 2024
→ Sep 2029
Phase 3Current
NCT03034239
1,824 pts·GBM
2024-03→2029-09·Not yet recruiting
1,824 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-09-113.4y awayPh3 Readout· GBM
Trial Timeline
Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P3
Not yet…
Catalysts
Ph3 Readout
2029-09-11 · 3.4y away
GBM
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03034239 | Phase 3 | GBM | Not yet recr... | 1824 | MRD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| Motainavolisib | Amgen | NDA/BLA | CD47 | |
| Rimaosocimab | Amgen | Preclinical | FXIa |